Compare Berkshire Hathaway Inc Class B (BRK.B) vs Cassava Sciences Inc (FLNA) Price & Performance

BRK.B trades at $491.2, down 1.13% for the day, with technical indicators showing a bullish bias from moving averages and a neutral stance from oscillators. Key support lies at $489 and resistance at $495. Analyst consensus is positive with 57% buy ratings, though fundamental data like P/E and profit margins are not provided in the snapshot.

The stock's outlook is supported by bullish technical signals and analyst optimism, but the lack of current fundamental metrics limits a full assessment. Risks include market volatility and dependence on broader economic conditions, while institutional sentiment remains a key driver for potential upside.

FLNA trades at $1.15, down 2.54% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company continues to report losses, with a net income of -$90.97M in 2025 and negative cash flow, though it has beaten EPS estimates for the last three quarters. Recent news highlights ongoing development in its TSC-related epilepsy therapies.

Despite consistent earnings beats, FLNA's negative profitability and cash burn pose significant risks. Analyst sentiment is positive with a 66.7% buy rating, but the stock's outlook depends heavily on clinical success and future funding. Investors should weigh the high-risk, high-reward nature of this biotech play.